Author:
Paoletti Xavier,Michiels Stefan
Reference38 articles.
1. Abramson RG. Overview of targeted therapies for cancer. 2016. https://www.mycancergenome.org/content/molecular-medicine/overview-of-targeted-therapies-for-cancer/ . Accessed 11 Oct 2016.
2. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang Y-K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
3. Belin L, Kamal M, Mauborgne C, Plancher C, Mulot F, Delord J-P, Goncalves A, Gavoille C, Dubot C, Isambert N, Campone M, Tredan O, Ricci F, Alt M, Loirat D, Sablin M-P, Paoletti X, Servois V, Le Tourneau C. Shiva: randomized phase ii trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer—pfs ratio from patients who crossed-over. Ann Oncol (34), 2016.
4. Buyse M, Michiels S. Omics-based clinical trial designs. Curr Opin Oncol. 2013;25(3):289–95.
5. Buyse M, Michiels S, Sargent DJ, Grothey A, Matheson A, de Gramont A. Integrating biomarkers in clinical trials. Expert Rev Mol Diagn. 2011;11(2):171–82.